BIOMARCADORES INFLAMATÓRIOS E TRANSTORNOS DEPRESSIVOS: IMPLICAÇÕES DIAGNÓSTICAS E TERAPÊUTICAS – REVISÃO SISTEMÁTICA INTEGRATIVA
Revista Científica Ipedss · 2026 · 06 (03)
DOI: 10.55703/27644006060303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Científica Ipedss, 2026. Verfasst von José Songlei da Silva Rocha und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To critically analyze the scientific evidence on the association between inflammatory biomarkers and depressive disorders, emphasizing their diagnostic, prognostic, and therapeutic implications.
Methods
A systematic integrative review was conducted in accordance with the PRISMA 2020 recommendations. Searches were performed in PubMed/MEDLINE, Scopus, Web of Science, Embase, PsycINFO, the Cochrane Library, and SciELO, covering publications available up to July 2026. Original studies involving adults were included when they investigated peripheral or central inflammatory biomarkers in association with depression, symptom profiles, neurobiological alterations, treatment response, or treatment resistance. The final sample comprised 35 publications, which were organized into four evidence domains: epidemiological and phenotypic associations; neuroinflammation and neurobiological mechanisms; prognostic and predictive value; and anti-inflammatory or immunomodulatory interventions. Due to substantial clinical and methodological heterogeneity, the findings were synthesized narratively.
Results
C-reactive protein and interleukin-6 were the most frequently investigated biomarkers and showed the most consistent associations with depression, neurovegetative symptoms, metabolic abnormalities, and treatment resistance. Inflammation was particularly associated with fatigue, anhedonia, sleep and appetite disturbances, reduced energy, and psychomotor slowing. Neuroimaging studies identified alterations consistent with neuroimmune activation, impaired corticostriatal reward circuitry, and changes in glutamatergic metabolism. Inflammatory biomarkers also showed potential to predict differential responses to antidepressants, physical exercise, electroconvulsive therapy, and anti-inflammatory interventions. However, trials involving infliximab, celecoxib, minocycline, and omega-3 fatty acids produced heterogeneous results, with more favorable effects primarily observed in subgroups presenting elevated baseline inflammation.
Conclusion
Inflammation represents a biologically relevant but non-universal dimension of depressive disorders. No single biomarker demonstrated sufficient performance for independent diagnostic use. The most promising applications involve identifying immunometabolic phenotypes, improving prognostic stratification, and personalizing treatment selection. Clinical implementation remains dependent on prospective validation, laboratory standardization, definition of clinically meaningful cutoff values, and biomarker-guided randomized trials. Keywords: Major Depressive Disorder; Biomarkers; Inflammation; Precision Medicine.
Zitieren
APA
Rocha, J. S. D. S., Guerreiro, I., & Soares, L. R. (2026). BIOMARCADORES INFLAMATÓRIOS E TRANSTORNOS DEPRESSIVOS: IMPLICAÇÕES DIAGNÓSTICAS E TERAPÊUTICAS – REVISÃO SISTEMÁTICA INTEGRATIVA. Revista Científica Ipedss, 06(03). https://doi.org/10.55703/27644006060303
Vancouver
Rocha JSDS, Guerreiro I, Soares LR. BIOMARCADORES INFLAMATÓRIOS E TRANSTORNOS DEPRESSIVOS: IMPLICAÇÕES DIAGNÓSTICAS E TERAPÊUTICAS – REVISÃO SISTEMÁTICA INTEGRATIVA. Revista Científica Ipedss. 2026;06(03). doi:10.55703/27644006060303
BibTeX
@article{Rocha2026,
author = {Rocha, José Songlei da Silva and Guerreiro, Isabel and Soares, Lismeia Raimundo},
title = {BIOMARCADORES INFLAMATÓRIOS E TRANSTORNOS DEPRESSIVOS: IMPLICAÇÕES DIAGNÓSTICAS E TERAPÊUTICAS – REVISÃO SISTEMÁTICA INTEGRATIVA},
journal = {Revista Científica Ipedss},
year = {2026},
volume = {06},
number = {03},
doi = {10.55703/27644006060303}
}
EUVIMED